Related Experiment Video

Updated: Jul 26, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.0K

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Habib Yaribeygi1, Mina Maleki2, Tannaz Jamialahmadi3,4

  • 1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.

EXCLI Journal
|June 22, 2023
PubMed

Insights

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) show promise for protecting the liver in diabetic patients. This review explores their potential benefits beyond glucose control for various liver conditions.

Area of Science:

  • Endocrinology
  • Hepatology
  • Pharmacology

Background:

  • Diabetic patients exhibit increased susceptibility to liver dysfunction.
  • Effective management of hyperglycemia is crucial for liver health in diabetes.
  • Emerging evidence suggests potential hepatoprotective roles for certain antidiabetic agents.

Purpose of the Study:

  • To review the current understanding of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) effects on liver complications.
  • To explore the potential mechanisms underlying the liver-protective effects of SGLT2 inhibitors.
  • To assess the utility of SGLT2 inhibitors as therapeutic agents for hepatic disorders in diabetic individuals.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of studies investigating SGLT2 inhibitors and liver function.
  • Synthesis of data on proposed mechanisms of action related to liver protection.

Main Results:

  • SGLT2 inhibitors demonstrate glucose-lowering efficacy.
  • Preliminary data suggest SGLT2 inhibitors may offer benefits beyond glycemic control for the liver.
  • Potential mechanisms include anti-inflammatory and antioxidant effects, and improvements in lipid metabolism.

Conclusions:

  • SGLT2 inhibitors represent a promising class of drugs for managing liver complications in diabetic patients.
  • Further research is warranted to fully elucidate their hepatoprotective potential and clinical applications.
  • These agents may offer a multi-faceted therapeutic approach for diabetic liver disease.
Keywords:
cirrhosisdiabetes mellitusfibrosishepatocellular carcinomalivernon-alcoholic fatty liver disorderssodium-glucose cotransporter-2 inhibitors

More Related Videos

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer16:59

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

11.8K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

289

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
121.6K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.3K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
210
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240